Joachim Listing Selected Research

Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)

1/2019	Progression of Structural Damage in the Sacroiliac Joints in Patients With Early Axial Spondyloarthritis During Long-Term Anti-Tumor Necrosis Factor Treatment: Six-Year Results of Continuous Treatment With Etanercept.
12/2016	Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years.
1/2016	Brief Report: Course of Active Inflammatory and Fatty Lesions in Patients With Early Axial Spondyloarthritis Treated With Infliximab Plus Naproxen as Compared to Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial.
1/2013	Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years.
11/2011	Relation of HLA-B27, tumor necrosis factor-α promoter gene polymorphisms, and T cell cytokine production in ankylosing spondylitis -- a comprehensive genotype-phenotype analysis from an observational cohort.
1/2010	Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.
2/2009	Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
7/2008	Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two.
3/2008	Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
1/2008	Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joachim Listing Research Topics

Disease

26	Ankylosing Spondylitis 01/2018 - 07/2003
21	Rheumatoid Arthritis 01/2020 - 07/2003
12	Inflammation (Inflammations) 01/2020 - 01/2008
9	Axial Spondyloarthritis 01/2019 - 01/2008
6	Sacroiliitis 01/2019 - 07/2008
6	Back Pain (Backache) 01/2018 - 02/2006
6	Necrosis 10/2017 - 07/2003
6	Arthritis (Polyarthritis) 01/2017 - 03/2002
5	Infections 01/2016 - 11/2005
5	Non-Radiographic Axial Spondyloarthritis 10/2014 - 01/2008
4	Osteitis 01/2019 - 01/2008
4	Rheumatic Diseases (Rheumatism) 01/2016 - 08/2010
3	Spondylarthritis (Spinal Arthritis) 01/2014 - 07/2008
3	Bacterial Infections (Bacterial Infection) 02/2009 - 12/2006
2	Adult-Onset Still's Disease 09/2021 - 01/2020
2	Osteoarthritis 01/2021 - 10/2014
2	Obesity 01/2020 - 01/2020
2	Ankylosis 02/2016 - 07/2003
2	Pain (Aches) 02/2006 - 03/2004
1	Lymphoma (Lymphomas) 12/2017
1	Melanoma (Melanoma, Malignant) 02/2017
1	Myocardial Infarction 01/2016
1	Osteoporosis 01/2016
1	Diabetes Mellitus 01/2016
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2016
1	Psoriasis (Pustulosis Palmaris et Plantaris) 05/2012
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2011
1	Neoplasms (Cancer) 01/2010
1	Uveitis 03/2009
1	Virus Diseases (Viral Diseases) 02/2009
1	Herpes Zoster 02/2009
1	Heart Failure 03/2008
1	Opportunistic Infections (Opportunistic Infection) 12/2006
1	Low Back Pain (Lumbago) 02/2006
1	Spondylarthropathies 03/2004
1	Psoriatic Arthritis 07/2003
1	Spinal Diseases (Disease, Spinal) 07/2003

Drug/Important Bio-Agent (IBA)

14	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019 - 03/2004
12	Tumor Necrosis Factor InhibitorsIBA 01/2020 - 07/2003
12	Etanercept (Enbrel)FDA Link 01/2019 - 07/2003
10	Antirheumatic Agents (DMARD)IBA 04/2018 - 03/2002
9	C-Reactive ProteinIBA 01/2019 - 03/2009
9	Infliximab (Remicade)FDA Link 01/2016 - 07/2003
9	Adalimumab (Humira)FDA Link 01/2014 - 07/2003
8	Biological ProductsIBA 01/2020 - 11/2005
7	Pharmaceutical PreparationsIBA 01/2020 - 09/2010
7	Methotrexate (Mexate)FDA LinkGeneric 10/2016 - 03/2002
6	HLA-B27 Antigen (HLA B27 Antigen)IBA 06/2013 - 07/2008
4	CytokinesIBA 09/2021 - 11/2011
4	Rituximab (Mabthera)FDA Link 01/2020 - 02/2013
4	Sulfasalazine (Azulfidine)FDA LinkGeneric 01/2019 - 07/2003
4	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 10/2017 - 10/2012
4	GlucocorticoidsIBA 01/2016 - 03/2008
3	O,O-diisopropyl-S-benzylthiophosphate (IBP)IBA 01/2018 - 02/2006
3	AntibodiesIBA 02/2009 - 12/2006
2	canakinumab FDA Link 09/2021 - 01/2020
2	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2021 - 10/2014
2	tocilizumab (atlizumab)FDA Link 01/2020 - 04/2018
2	Acute-Phase Proteins (Acute-Phase Protein)IBA 05/2012 - 03/2004
1	Abatacept (Orencia)FDA Link 01/2020
1	InterleukinsIBA 01/2020
1	amsonic acid (DAS)IBA 01/2020
1	factor AIBA 10/2017
1	Celecoxib (Celebrex)FDA Link 10/2017
1	AdipokinesIBA 01/2017
1	AdiponectinIBA 01/2017
1	LeptinIBA 01/2017
1	HLA-DRB4 Chains (HLA DRB4)IBA 10/2016
1	Diclofenac (SR 38)FDA LinkGeneric 08/2016
1	Naproxen (Naprosyn)FDA LinkGeneric 01/2016
1	Leflunomide (Arava)FDA LinkGeneric 11/2014
1	N 30IBA 10/2014
1	Ustekinumab (CNTO 1275)FDA Link 05/2014
1	brassIBA 08/2010
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 01/2010
1	Proteins (Proteins, Gene)FDA Link 02/2009
1	Monoclonal AntibodiesIBA 02/2009
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 03/2008
1	Biomarkers (Surrogate Marker)IBA 01/2008
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2008
1	Complement System Proteins (Complement)IBA 11/2006

Therapy/Procedure

16	Therapeutics 01/2020 - 07/2003
9	Biological Therapy 01/2020 - 01/2006
1	Retreatment 03/2007